^
Association details:
| Biomarker: | FLT3 mutation + NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) + RMC-7977 (RAS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2793 RASMULTI(ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models
Published date:
11/02/2023
Excerpt:
The combination of RMC-7977 and gilteritinib had superior activity in mixtures containing FLT3 and FLT3-NRAS co-mutations, but no additional benefit over RMC-7977 monotherapy in cells harboring NRAS mutations alone.
